Avalo Therapeutics (AVTX) Competitors $4.88 +0.17 (+3.61%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. NVCT, INBX, PRQR, MNPR, ELDN, ESPR, VYGR, DERM, DMAC, and OGIShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Nuvectis Pharma (NVCT), Inhibrx (INBX), ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), DiaMedica Therapeutics (DMAC), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Nuvectis Pharma Inhibrx ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Organigram Nuvectis Pharma (NASDAQ:NVCT) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation. Do insiders & institutionals have more ownership in NVCT or AVTX? 96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 30.5% of Nuvectis Pharma shares are held by company insiders. Comparatively, 3.0% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor NVCT or AVTX? Nuvectis Pharma and Avalo Therapeutics both received 13 outperform votes by MarketBeat users. However, 92.86% of users gave Nuvectis Pharma an outperform vote while only 50.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes1392.86% Underperform Votes17.14%Avalo TherapeuticsOutperform Votes1350.00% Underperform Votes1350.00% Does the media refer more to NVCT or AVTX? In the previous week, Avalo Therapeutics had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Avalo Therapeutics and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.96 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Overall Sentiment Nuvectis Pharma Very Positive Avalo Therapeutics Positive Which has more volatility & risk, NVCT or AVTX? Nuvectis Pharma has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Do analysts prefer NVCT or AVTX? Nuvectis Pharma presently has a consensus price target of $17.00, suggesting a potential upside of 92.53%. Avalo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 514.75%. Given Avalo Therapeutics' higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NVCT or AVTX more profitable? Nuvectis Pharma's return on equity of -155.80% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Avalo Therapeutics N/A -442.16%122.99% Which has better earnings & valuation, NVCT or AVTX? Nuvectis Pharma has higher earnings, but lower revenue than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.13-7.81Avalo Therapeutics$441K119.82-$31.54MN/AN/A SummaryNuvectis Pharma and Avalo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.84M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / Sales119.82262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.546.597.064.69Net Income-$31.54M$143.75M$3.23B$248.14M7 Day Performance12.70%3.72%2.67%2.39%1 Month Performance22.00%11.01%8.82%6.05%1 Year Performance-57.53%3.87%31.44%13.60% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.6044 of 5 stars$4.88+3.6%$30.00+514.8%-57.3%$52.84M$441K0.0040News CoverageShort Interest ↓NVCTNuvectis Pharma2.8221 of 5 stars$8.98-4.6%$17.00+89.3%+33.2%$187.63MN/A-7.748Positive NewsINBXInhibrx3.1086 of 5 stars$12.96-3.8%N/A-12.8%$187.61M$200K0.11166Positive NewsUpcoming EarningsPRQRProQR Therapeutics3.0236 of 5 stars$1.78+7.2%$8.00+349.4%-0.5%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics3.252 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.624 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Gap UpESPREsperion Therapeutics4.1847 of 5 stars$0.92+8.1%$6.25+580.4%-58.3%$182.07M$259.57M-1.44200Options VolumeAnalyst RevisionVYGRVoyager Therapeutics4.4289 of 5 stars$3.29+20.1%$13.39+307.0%-61.0%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionHigh Trading VolumeDERMJourney Medical2.3228 of 5 stars$7.81-3.1%$9.88+26.4%+21.7%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.347 of 5 stars$4.17+1.5%$8.00+91.8%+54.4%$178.82MN/A-7.4520Short Interest ↑OGIOrganigram0.7651 of 5 stars$1.31-3.0%N/A-7.3%$175.39M$194.09M-3.45860Positive News Related Companies and Tools Related Companies Nuvectis Pharma Competitors Inhibrx Competitors ProQR Therapeutics Competitors Monopar Therapeutics Competitors Eledon Pharmaceuticals Competitors Esperion Therapeutics Competitors Voyager Therapeutics Competitors Journey Medical Competitors DiaMedica Therapeutics Competitors Organigram Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTX Stock Free AVTX Stock Alerts